Stockwinners Market Radar for November 20, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

Settings & Search

ALK...		Hot Stocks 20:05 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Airlines and regulators are pushing to have just one pilot in the cockpit of passenger jets instead of two. It would lower costs and ease pressure from crew shortages, but placing such responsibility on a single person at the controls is unsettling for some, Bloomberg's Angus Whitley reports. Over 40 countries including Germany, the U.K. and New Zealand have asked the United Nations body that sets aviation standards to help make single-pilot flights a safe reality, the author notes. The European Union Aviation Safety Agency has also been working with planemakers to determine how solo flights would operate and preparing rules to oversee them. EASA said such services could start in 2027. Publicly traded companies in the space include Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Southwest (LUV), Spirit Airlines (SAVE) and United Airlines (UAL). 2. Walmart (WMT) health-care executive Cheryl Pegus will join JPMorgan's (JPM) Morgan Health venture as a managing director, with aims to improve employer-sponsored health care, Bloomberg's John Tozzi reports. The move creates a vacancy at the nation's largest retailer, as rivals like Amazon.com (AMZN) and CVS Health (CVS) broaden their reach into the $4 trillion U.S. health-care industry, the author notes. It's also a high-profile hire for Morgan Health, which the bank launched last year after shutting its joint venture with Amazon and Berkshire Hathaway (BRK.A; BRK.B), known as Haven. 3. While generally "pretty bullish" in his column about the outlook for Apple (AAPL) stock, Eric J. Savitz writes in this week's edition of Barron's that he now sees reasons for concern - growth is slowing, and might go negative, and valuation is elevated. Apple shares look vulnerable, the author says, noting that the company is seeing its pandemic boost wear off. Brace for a down year in 2023, he argues. 4. Marvel and Disney's (DIS) "Black Panther: Wakanda Forever" stayed atop the domestic box office with another $67.3M for a 10-day domestic cume of $288M and $546M globally. The movie had hoped to clear $70 million in its sophomore outing but fell 63%, a bit more than expected. 5. American Tower's (AMT), SBA Communications (SBAC), Crown Castle's (CCI), Match (MTCH), and Activision Blizzard (ATVI) saw a positive mention in this week's edition of Barron's.
PSTV		Hot Stocks 15:27 EST Plus Therapeutics provides updates on ReSPECT clinical trials - Plus Therapeutics presented data from two ongoing clinical trials evaluating the company's lead investigational targeted radiotherapeutic, rhenium obisbemeda, in recurrent glioblastoma, leptomeningeal metastases, as well as clinical trial plans for pediatric brain cancer at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology. The oral presentation titled, Report of the ReSPECT-GBM Phase 1/2a Dose Escalation Trial of Rhenium-186 NanoLiposome in Recurrent Glioma via Convection Enhanced Delivery & Planned Phase 2b Trial, included the following key findings: In 24 patients with recurrent glioblastoma, a single dose of rhenium obisbemeda was administered in the dose escalation phase, achieving up to 740 Gray of absorbed radiation dose to the tumor. Between one to four intracranial CED catheters have been placed in each patient and there have been no dose limiting toxicities and a good safety profile has been observed. A statistically significant improvement in overall survival correlated with both the average absorbed dose of radiation to the tumor and the percent volume of tumor treated, specifically: A 100 Gy increase in the absorbed dose correlated with a 35.7% decrease in the risk of death; A 1% increase in tumor volume treated is associated with a 4.5% decrease in the risk of death. A recommended Phase 2 dose of 22.3 mCi in 8.8 mL is being studied for tumor volumes of 20 mL or less and is expected to enroll up to an additional 31 patients. Continued dose escalation will be performed to assess the potential to treat tumors larger than 20 mL. The Company's second oral presentation titled, Preclinical Data and Initial Clinical Experience in the Phase 1/2a Dose Escalation Trial of Rhenium-186 Nanoliposome in Leptomeningeal Metastases: the ReSPECT-LM Trial, highlighted data from the first two cohorts which demonstrates the potential of rhenium obisbemeda to treat LM: As single rhenium obisbemeda dose administered through an intraventricular catheter at 6.6 mCi in 5.0 mL in Cohort 1 achieved absorbed doses of 18.7 to 29.0 Gy to the ventricles and cranial subarachnoid space, which was well tolerated with no treatment-related adverse events of greater than grade 1. All four patients treated to date in Cohorts 1 and 2 were observed to have prompt and complete rhenium obisbemeda distribution throughout the cerebrospinal fluid subarachnoid space that was durable to 28 days. All patients showed a decreased CSF tumor cell count by microfluidic chamber assay after treatment, ranging from 46% to 92%. In November 2022, Plus Therapeutics, in collaboration with Lurie Children's Hospital investigators, anticipates filing an Investigational New Drug application for a first-in-child Phase 1/2a clinical trial to determine the maximum tolerated dose, safety, tolerability and early efficacy of rhenium obisbemeda in supratentorial recurrent or progressive pediatric ependymoma and high-grade glioma in up to 24 patients initially. These plans were presented in a poster titled, A two-part, Phase 1 study of Rhenium-186 NanoLiposome delivered by convection enhanced delivery for recurrent or progressive childhood ependymoma and high-grade glioma.